| 1 | Biological: Benralizumab, Biological: Placebo to Mepolizumab (Nucala) | 2件: Benralizumab Benralizumab, Mepolizumab (Nucala) | 2件: Mepolizumab
Mepolizumab
(Nucala),
Benralizumab
💬
| 2件: IL5 IL5, IL5RA 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 💬
|
| 2 | Biological: Mepolizumab, Biological: Placebo to Benralizumab (Nucala) | 2件: Benralizumab Benralizumab, Mepolizumab (Nucala) | 2件: Mepolizumab
Mepolizumab
(Nucala),
Benralizumab
💬
| 2件: IL5 IL5, IL5RA 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 💬
|
| 3 | Mepolizumab (Nucala) | 1件: Mepolizumab Mepolizumab (Nucala) | 1件: Mepolizumab
Mepolizumab
(Nucala) 💬
| 1件: IL5 IL5 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 4件: 44 44, 45, 98, 162 💬
|
| 4 | Mepolizumab (a-IL-5 antibody) (Nucala) | 1件: Mepolizumab Mepolizumab (Nucala) | 1件: Mepolizumab
Mepolizumab
(Nucala) 💬
| 1件: IL5 IL5 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 162 162 💬
|
| 5 | Mepolizumab 100 mg (Nucala) | 1件: Mepolizumab Mepolizumab (Nucala) | 1件: Mepolizumab
Mepolizumab
(Nucala) 💬
| 1件: IL5 IL5 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 💬
|
| 6 | Mepolizumab 300 mg (Nucala) | 1件: Mepolizumab Mepolizumab (Nucala) | 1件: Mepolizumab
Mepolizumab
(Nucala) 💬
| 1件: IL5 IL5 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 💬
|
| 7 | NUCALA | 1件: Mepolizumab Mepolizumab (Nucala) | 1件: Mepolizumab
Mepolizumab
(Nucala) 💬
| 1件: IL5 IL5 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 45 💬
|
| 8 | Nucala 100 mg powder for solution for injection | 1件: Mepolizumab Mepolizumab (Nucala) | 1件: Mepolizumab
Mepolizumab
(Nucala) 💬
| 1件: IL5 IL5 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 45 💬
|
| 9 | NUCALA® | 1件: Mepolizumab Mepolizumab (Nucala) | 1件: Mepolizumab
Mepolizumab
(Nucala) 💬
| 1件: IL5 IL5 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 💬
|
| 10 | SB-240563 (mepolizumab) (Nucala) | 1件: Mepolizumab Mepolizumab (Nucala) | 1件: Mepolizumab
Mepolizumab
(Nucala) 💬
| 1件: IL5 IL5 💬
| 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 45 💬
|